Allergy Therapeutics plc (AGY) Fair Value & Analysis
Healthcare · GB · Market cap 602M GBX
Fair value as of: Jun 23, 2026
From 3 valuation models · updated 7 days ago
Share price −22.2% over the past month.
Price vs Fair Value (12 months)
12‑month range £0.0726 – £0.1255 · fair‑value band £0.0200 – £0.0400 · the £0.0726 price screens above the £0.0300 fair value. As of Jun 23, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Allergy Therapeutics plc (AGY) currently trades at £0.0726, while our model-based Fair Value estimate is £0.0300 — implying the stock looks roughly 58.7% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, Allergy Therapeutics plc generated revenue of £57.3M at a net margin of -84.1%. Revenue grew 6.6% year over year. Net debt stands at £47.5M. Fundamentals as of Jun 23, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 23, 2026. TTM = trailing twelve months.
About the company
Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics products. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics, and Acarovac Plus. It also develops Grass MATA MPL, a subcutaneous allergen-specific immunotherapy candidate that aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen; and VLP Peanut, a short-course peanut allergy vaccine. Allergy Therapeutics plc was founded in 1998 and is headquartered in Worthing, the United Kingdom.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Allergy Therapeutics plc reported revenue of £55.0M in FY2025 versus £84.3M in FY2021, a compound −10.1%/yr. Reported net income was −£40.1M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 23, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥49.36 | ¥30.99 | -37% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$26.19 | R$26.01 | -1% |
| Hansoh Pharmaceutical Group 3692 | HK$29.32 | HK$23.94 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,623 | ₹1,461 | -78% |
| Swedish Orphan Biovitrum AB SOBI | kr 444.80 | kr 440.64 | -1% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Allergy Therapeutics plc (AGY) undervalued?
What is the fair value of AGY?
What is the quality score of AGY?
What is the revenue of Allergy Therapeutics plc (AGY)?
What is the net profit margin of AGY?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.